MK-2206 is under clinical development by Merck and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MK-2206’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MK-2206 overview

MK-2206 is under development for the treatment of prostate cancer, non-small cell lung cancer, metastatic breast cancer, small cell lung cancer, thymic malignancies and small lymphocytic lymphoma (SLL) and melanoma. The drug candidate is administered by orally. MK-2206 is a selective non-ATP competitive allosteric Akt inhibitor.

It was also under development for endometrial cancer, recurrent platinum-resistant ovarian, fallopian tube, peritoneal cancer, colorectal carcinoma, malignant glioma, HER-2 positive breast cancer, metastatic neuroendocrine tumors, head and neck cancer, metastatic pancreatic cancer, metastatic nasopharyngeal carcinoma, hepatocellular carcinoma, relapsed or refractory acute myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed or refractory diffuse large B-cell lymphoma, refractory biliary cancer, gastric cancer, gastroesophageal junction cancer, chronic lymphocytic leukemia (CLL), bile duct cancer (Cholangiocarcinoma), metastatic adenoid cyst carcinoma and gallbladder cancer.

Merck overview

Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

For a complete picture of MK-2206’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.